Voyager Therapeutics (VYGR) Projected to Post Earnings on Tuesday

Key Points

• Voyager Therapeutics (NASDAQ: VYGR) is set to release its Q2 2025 earnings on August 5th, with analysts anticipating a loss of ($0.48) per share on revenue of $9.50 million.
• The company's previous earnings report showed a loss of ($0.53) per share and revenue of $6.47 million, falling short of analyst expectations.
• HC Wainwright has reiterated a "buy" rating on VYGR shares with a price target of $30.00, reflecting positive outlook from analysts despite recent performance struggles.

Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) is expected to be posting its Q2 2025 quarterly earnings results before the market opens on Tuesday, August 5th. Analysts expect Voyager Therapeutics to post earnings of ($0.48) per share and revenue of $9.50 million for the quarter.

Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.18). The firm had revenue of $6.47 million for the quarter, compared to analysts' expectations of $13.55 million. Voyager Therapeutics had a negative net margin of 126.49% and a negative return on equity of 27.36%. On average, analysts expect Voyager Therapeutics to post $-1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Voyager Therapeutics Price Performance

Shares of VYGR stock traded down $0.21 during mid-day trading on Friday, hitting $2.98. 711,648 shares of the stock traded hands, compared to its average volume of 494,803. The stock has a market cap of $164.69 million, a P/E ratio of -2.04 and a beta of 0.85. The stock's fifty day moving average is $3.19 and its two-hundred day moving average is $3.72. Voyager Therapeutics has a 52-week low of $2.64 and a 52-week high of $8.53.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a "buy" rating and issued a $30.00 price objective on shares of Voyager Therapeutics in a research report on Tuesday, April 8th. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus price target of $13.39.

Hedge Funds Weigh In On Voyager Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. Jacobs Levy Equity Management Inc. acquired a new stake in shares of Voyager Therapeutics during the 1st quarter worth approximately $218,000. Acadian Asset Management LLC grew its stake in shares of Voyager Therapeutics by 863.3% during the 1st quarter. Acadian Asset Management LLC now owns 230,708 shares of the company's stock worth $778,000 after purchasing an additional 206,758 shares during the period. Finally, AQR Capital Management LLC grew its stake in shares of Voyager Therapeutics by 179.3% during the 1st quarter. AQR Capital Management LLC now owns 495,260 shares of the company's stock worth $1,674,000 after purchasing an additional 317,927 shares during the period. Institutional investors and hedge funds own 48.03% of the company's stock.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.